Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

Phase 1

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CMV Specific Cytotoxic T Lymphocytes (CTL)

First Posted Date: 2009-10-06

Last Posted Date: 2018-05-02

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 25

Registration Number: NCT00990496

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia
Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts
Secondary Acute Myeloid Leukemia

Interventions: Biological: Pretargeted Radioimmunotherapy
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-10-02

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00988715

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Infusion of Expanded Cord Blood T Cells

Phase 1

Withdrawn

Conditions: Stem Cell Transplantation
Leukemia
Lymphoma
Pediatric Disorders

Interventions: Drug: Melphalan
Radiation: Total Body Irradiation (TBI)
Drug: Thiotepa
Drug: Fludarabine
Drug: Etoposide
Drug: Rituximab
Drug: Anti-thymocyte globulin (ATG)
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: G-CSF
Procedure: Ex vivo expanded T cell Infusion

First Posted Date: 2009-09-04

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00972101

Sickle Cell Disease Conditioning for Bone Marrow Transplant

Phase 1

Completed

Conditions: Bone Marrow Transplantation
Sickle Cell Disease

Interventions: Drug: fludarabine

First Posted Date: 2009-08-28

Last Posted Date: 2017-07-25

Lead Sponsor: Emory University

Target Recruit Count: 8

Registration Number: NCT00968162

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Children's National Medical Center, Washington, D.C., District of Columbia, United States

and more 7 locations

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

Phase 1

Terminated

Conditions: Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: Total body irradiation
Biological: Umbilical cord blood unit with C3a fragment
Biological: Unmanipulated UCB Unit

First Posted Date: 2009-08-24

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 31

Registration Number: NCT00963872

Locations: 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States

Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Phase 2

Conditions: Hematopoietic/Lymphoid Cancer

First Posted Date: 2009-08-14

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 60

Registration Number: NCT00959231

Locations: 🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧
UCL Cancer Institute, London, England, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, England, United Kingdom

and more 3 locations

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-08-13

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 37

Registration Number: NCT00958854

Locations: 🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, Exeter, England, United Kingdom

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Not Applicable

Completed

Conditions: Congenital Pediatric Disorders

Interventions: Drug: Busulfan
Drug: Cytoxan
Drug: Fludarabine
Procedure: Cord Blood Stem Cell Infusion

First Posted Date: 2009-08-03

Last Posted Date: 2023-10-30

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 40

Registration Number: NCT00950846

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Melphalan
Procedure: Autologous Stem Cell Transplant
Drug: Fludarabine
Procedure: Allogeneic Stem Cell Transplant

First Posted Date: 2009-07-29

Last Posted Date: 2019-09-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 124

Registration Number: NCT00948922

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy